This is an old revision of this page, as edited by ElBenevolente (talk | contribs) at 06:37, 30 January 2004 (Added new FDA indication). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:37, 30 January 2004 by ElBenevolente (talk | contribs) (Added new FDA indication)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Olanzapine (Zyprexa, Symbyax) is one of the atypical antipsychotic medications. Olanzapine has been FDA approved for the treatment of schizophrenia, acute mania in bipolar disorder, and as maintenance treatment in bipolar disorder. The anti-psychiatry website Prozac Spotlight argues that a 1999 study demonstrated that the drug was ineffective in treatment of Parkinson's disease.
In December 2003 the FDA approved Symbyax to treat bipolar depression. Symbyax is a combination of fluoxetine and olanzapine.
Side Effects
Common side effects include muscle-rigidity, muscle-stiffness, muscle-twitches, restlesness, sedation, and weight-gain. Olanzapine is reported to cause tardive dyskinesia and neurological malignant syndrome.
Olanzapine is manufactured by Eli Lilly (NYSE: LLY).